TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE
6.1. Overview
6.2. Corticosteroids
6.3. Antibiotics
6.4. Analgesics
6.5. Antivirals
6.6. Antifungals
6.7. Other treatment types
7. OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Topical
7.3. Oral
7.4. Injectables
8. OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION
8.1. Overview
8.2. Uveitis
8.3. Conjunctivitis
8.4. Keratitis
8.5. Scleritis
8.6. Retinitis
8.7. Other indications
9. OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE
9.1. Overview
9.2. Infectious causes
9.3. Trauma and injury
9.4. Autoimmune diseases
9.5. Other causes
10. OCULAR INFLAMMATION TREATMENT MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Ocular Inflammation Treatment Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Ocular Inflammation Treatment Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2023
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. ALIMERA SCIENCES
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Bausch Health Companies Inc.
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. EyePoint Pharmaceuticals, Inc.
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Ocular Therapeutix, Inc.
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. PFIZER INC.
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Santen Pharmaceutical Co., Ltd.
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 OCULAR INFLAMMATION TREATMENT MARKET, SYNOPSIS, 2019-2032
TABLE 2 OCULAR INFLAMMATION TREATMENT MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 4 OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 5 OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 6 OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 11 US: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 12 US: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 13 US: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 14 US: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 15 CANADA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 16 CANADA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 17 CANADA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 3 EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 4 EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 7 GERMANY: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 8 GERMANY: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 10 FRANCE: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 11 FRANCE: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 12 FRANCE: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 13 ITALY: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 14 ITALY: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 15 ITALY: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 16 ITALY: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 17 SPAIN: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 18 SPAIN: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 19 SPAIN: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 20 SPAIN: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 21 UK: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 22 UK: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 23 UK: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 24 UK: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 33 JAPAN: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 34 JAPAN: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 35 JAPAN: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 36 JAPAN: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 37 CHINA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 38 CHINA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 39 CHINA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 40 CHINA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 41 INDIA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 42 INDIA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 43 INDIA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 44 INDIA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 45 AUSTRALIA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 46 AUSTRALIA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 47 AUSTRALIA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 48 AUSTRALIA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 65 AFRICA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 66 AFRICA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 67 AFRICA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 68 AFRICA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY TREATMENT TYPE, 2019-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, BY CAUSE, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE OCULAR INFLAMMATION TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE OCULAR INFLAMMATION TREATMENT MARKET
FIGURE 4 OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY TREATMENT TYPE, 2023
FIGURE 5 OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION , 2023
FIGURE 6 OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY INDICATION, 2023
FIGURE 7 OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY CAUSE, 2023
FIGURE 8 OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 NORTH AMERICA: OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 EUROPE: OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 ASIA-PACIFIC: OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 REST OF THE WORLD: OCULAR INFLAMMATION TREATMENT MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 OCULAR INFLAMMATION TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ABBVIE INC.: SWOT ANALYSIS
FIGURE 16 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 ALIMERA SCIENCES: SWOT ANALYSIS
FIGURE 18 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS
FIGURE 20 EYEPOINT PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 EYEPOINT PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 22 NOVARTIS AG.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 24 OCULAR THERAPEUTIX, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 OCULAR THERAPEUTIX, INC.: SWOT ANALYSIS
FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 PFIZER INC.: SWOT ANALYSIS
FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SANTEN PHARMACEUTICAL CO., LTD.: SWOT ANALYSIS
